Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo BioSciences Licenses Protein Expression Technology to Novo Nordisk

NEW YORK, Sept. 7 (GenomeWeb News) - Sangamo BioSciences has licensed its zinc finger DNA-binding protein technology to Novo Nordisk, the companies said today.


Novo Nordisk, based in Bagsvaerd, Denmark, plans to evaluate the technology for enhanced protein production.


Sangamo, located in Richmond, Calif., said it has engineered zinc finger protein transcription factors that can increase protein production from genes.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.